title: Heparin and protamine use in peripheral vascular surgery: a comparison between surgeons of the Society for Vascular Surgery and the European Society for Vascular Surgery.
abstract: It was the intent of this study to document, in general, the patterns and complications of heparin and protamine usage during carotid endarterectomy, aortic and femoral-popliteal-tibial reconstructions for occlusive disease, elective and emergent abdominal aortic aneurysmectomy, thromboembolectomy, and dialysis arteriovenous (AV) fistula placement by surgeons from North America and Europe. All vascular surgeons from the Society for Vascular Surgery (SVS) and the European Society for Vascular Surgery (ESVS) were surveyed by a voluntary, self-reported questionnaire. Six hundred and forty-six completed questionnaires (284 from SVS and 362 from ESVS), representing a 62% response rate, were returned for evaluation. Systemic and regional administration of heparin was common during vascular procedures performed by both SVS and ESVS surgeons. Use of protamine to reverse heparin anticoagulation varied among SVS and ESVS surgeons, respectively, during: carotid endarterectomy (54% vs. 26%, p < 0.01), elective aortic reconstruction for occlusive disease (58% vs. 23%, p < 0.001), elective aortic reconstruction for abdominal aortic aneurysm (63% vs. 27%, p < 0.001), and femoral-popliteal-tibial reconstruction (44% vs. 15%, p < 0.001). Adverse reactions to protamine among the 25,219 and 12,902 cases reported from SVS and ESVS surgeons, respectively, included: hypotension (1209 and 495 cases), pulmonary artery hypertension (65 and eight cases), anaphylaxis (52 and 10 cases), and death (seven and two cases). These adverse responses accounted for 5.3% and 4.0% of the SVS and ESVS cases, respectively. Although this study is subject to the known limitations of a retrospective survey, it is clear that heparin use is common. Protamine reversal of heparin anticoagulation is more common in North America.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Surgery, University of Michigan Medical Center, Ann Arbor 48109-0329.
authors.forename: T W
authors.initials: TW
authors.lastname: Wakefield
authors.forename: B
authors.initials: B
authors.lastname: Lindblad
authors.forename: T J
authors.initials: TJ
authors.lastname: Stanley
authors.forename: B J
authors.initials: BJ
authors.lastname: Nichol
authors.forename: J C
authors.initials: JC
authors.lastname: Stanley
authors.forename: D
authors.initials: D
authors.lastname: Bergqvist
authors.forename: L J
authors.initials: LJ
authors.lastname: Greenfield
authors.forename: S E
authors.initials: SE
authors.lastname: Bergentz
mesh_terms: D003625:Data Collection; D004363:Drug Utilization / Q000706:statistics & numerical data*; D005060:Europe; D006493:Heparin / Q000627:therapeutic use*; D006801:Humans; D009656:North America; D016491:Peripheral Vascular Diseases / Q000601:surgery*; D010818:Practice Patterns, Physicians'; D011479:Protamines / Q000009:adverse effects* / Q000627:therapeutic use*; D012189:Retrospective Studies; D012955:Societies, Medical; D011795:Surveys and Questionnaires; D014656:Vascular Surgical Procedures / Q000592:standards*
chemical_list: D011479:Protamines; D006493:Heparin